Browse the latest research summaries in the field of musculoskeletal medicine for spinal cord injury patients and caregivers.
Showing 51-60 of 278 results
The Journal of Spinal Cord Medicine, 2024 • January 1, 2024
This study explored the knowledge and awareness of bone loss and fracture risk among adults with SCI. It revealed that a significant portion of participants were unfamiliar with BMD and felt their kno...
KEY FINDING: Approximately 20% of participants had never heard of bone mineral density (BMD).
Inflammation, 2024 • April 1, 2024
This study investigates the therapeutic potential of GlyNAC (glycine and N-acetylcysteine) in treating spinal cord injury (SCI) by reducing oxidative stress and skeletal muscle atrophy in a rat model....
KEY FINDING: GlyNAC treatment significantly elevated BBB scores from the first to the eighth week after intervention, suggesting improved motor function recovery in rats with SCI.
Global Spine Journal, 2025 • February 1, 2025
This study investigates the treatments and outcomes of hangman’s fractures in geriatric patients using a large multicenter database in Japan. The study reveals a high bony fusion rate with appropriate...
KEY FINDING: The bony fusion rate for hangman’s fractures in the geriatric population was high, around 90% for Type I and Type II fractures.
JBMR Plus, 2023 • December 1, 2023
The study demonstrates the efficacy of Siglec-15 Ab (NP159) in reducing bone resorption after acute SCI while maintaining bone formation capacity in rats. NP159 almost fully prevents the SCI-induced l...
KEY FINDING: NP159 treatment almost completely prevents the deterioration of bone after SCI, including loss of bone mineral density, trabecular bone volume, trabecular connectivity, and bone stiffness.
Top Spinal Cord Inj Rehabil, 2023 • January 1, 2023
The study developed SCI-FX, a preliminary risk score to estimate 5-year lower extremity fragility fracture risk among patients living with chronic spinal cord injury (cSCI). The model incorporates fac...
KEY FINDING: A simple model was identified to estimate 5-year fracture risk among patients with cSCI based on their total score.
BMC Musculoskeletal Disorders, 2024 • January 9, 2024
This retrospective, cross-sectional study compared osteoporosis prevalence in Korean adults with SCI using different BMDRV: region-based from DXA manufacturers (TDXA) and international based on NHANES...
KEY FINDING: The prevalence of osteoporosis was significantly higher using the NHANES III reference (TNHA) compared to the DXA manufacturer's reference (TDXA) in both males and females.
Virtual Reality, 2024 • April 7, 2024
This systematic review aimed to find effective virtual rehabilitation methods for physical improvement and engagement in people with osteoporosis or musculoskeletal disorders. The review identified fo...
KEY FINDING: Different virtual rehabilitation devices offer varying degrees of immersion and physical improvement.
Journal of Cachexia, Sarcopenia and Muscle, 2024 • May 19, 2024
This study investigates the time course of molecular changes in rat soleus muscle following severe spinal cord injury (SCI) to identify therapeutic targets and windows for treating muscle wasting. The...
KEY FINDING: SCI induces early and transient expression of extracellular matrix (ECM) remodeling genes, leading to muscle fibrosis.
Frontiers in Pharmacology, 2024 • May 15, 2024
This editorial highlights the potential of natural products, medicinal foods, and herbal medicines in treating bone metabolism diseases and bone-related tumors. The included research articles explore ...
KEY FINDING: Tea-Seed Oil (TSO) contains components with antibacterial properties, potentially acting through pathways like PI3K-AKT and MAPK.
JBMR Plus, 2024 • June 7, 2024
One year of romosozumab treatment in women with chronic SCI increased DXA-derived aBMD at the lumbar spine and hip. These results were congruent with CT results at the hip, which indicated increases i...
KEY FINDING: After 12 mo of treatment, areal BMD at the lumbar spine and total hip were significantly increased with median changes of 10.2% (IQR: 8.3–15.2%, p<.001) and 4.2% (IQR: 3.4–7.7%, p = .009), respectively.